← All stocks

LIGAND PHARMACEUTICALS INC

LGND Net selling

CIK 0000886163 #1265 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$1.77M

$1.43M on a plan · $0.00 straight out of an exercise

Sold at will

$342.00K

1 of 6 sales

Net

−$1.77M

−$342.00K against sales at will

By person

11 insiders · 6 transactions

78.4×

Todd C. Davis holds 78.4 times base salary in stock. $56.86M of shares against $724.50K in salary for 2025.

Salary from the company's own proxy. The shares are what Todd C. Davis last reported holding, valued at $285.00, the price Common Stock was last bought or sold at on the open market here, on 10 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Reardon Andrew

CLO & Secretary

—

$1.43M (5) scheduled

−$1.43M

36,514

0.1832%

$10.41M

+68.6%

Zimmermann Martine

Director

—

$342.00K (1)

−$342.00K

3,897

0.0195%

$1.11M

+10.2%

Davis Todd C

Chief Executive Officer

—

199,513

1.00%

$56.86M

+62.2%

Aryeh Jason

Director

—

102,580

0.5146%

$29.24M

−9.6%

Korenberg Matthew E

President & COO

—

50,777

0.2547%

$14.47M

−2.5%

KOZARICH JOHN W

Director

—

42,622

0.2138%

$12.15M

−2.6%

Sabba Stephen L

Director

—

33,629

0.1687%

$9.58M

+11.4%

Espinoza Octavio

Chief Financial Officer

—

27,696

0.1389%

$7.89M

+5.9%

LAMATTINA JOHN L

Director

—

26,969

0.1353%

$7.69M

−8.6%

Gray Nancy Ryan

Director

—

8,930

0.0448%

$2.55M

+29.7%

Haas Jason

Director

—

3,981

0.0200%

$1.13M

−26.2%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 2

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 5

Sales straight out of an exercise 0

Sales at will 1

Transactions with no price 0

Shares from compensation/vesting 0

History held since 6 Sep 2016